At Photocure, we believe that a strong culture begins with its leadership. That is how we create a cohesive network of colleagues, working closely together towards the same goals. We believe in exercising the highest levels of accountability, integrity and transparency in order to succeed in our common goal of achieving the best healthcare for every patient with bladder cancer.
Board of Directors
Jan H. Egberts, Chairperson of the Board
Dr. Egberts has over 25 years of experience in the pharmaceutical and medical devices sector. Currently, Dr. Egberts serves as the Managing Partner of Veritas Investments, a private investment company focused on minority and controlling investments in healthcare companies.
Dr. Egberts gained his medical degree from Erasmus University Medical School in the Netherlands and pursued the clinical part of his medical training at Harvard Medical School. Dr. Egberts also obtained an MBA from Stanford University.
After Stanford, he joined McKinsey & Co. as a strategic consultant in New York. Dr. Egberts subsequently held various business development and general management positions of increasing responsibility in the USA at Merck & Co. and Johnson & Johnson. Thereafter, he served as Senior Advisor, Healthcare Investments for 3i, the private equity firm. Dr. Egberts then became CEO of OctoPlus, a publicly traded specialty pharmaceutical company in the Netherlands. OctoPlus was subsequently acquired by Dr. Reddy Laboratories. After this, Dr. Egberts joined Agendia, a molecular diagnostics company, initially as board member and subsequently full time as interim CEO. Dr. Egberts also has held over 15 executive and non-executive supervisory board positions in the U.S. and various European countries.
Jan Egberts holds 14,500 shares in Photocure.
He is Member of the Compensation Committee.
Johanna Holldack, Director
Dr. Holldack has international operational experience from pharma companies, including clinical trials, drug approvals, IPOs and licensing. She has also managed several mergers and acquisitions. In addition, Dr. Holldack has venture capital experience from Swiss-based Aravis Venture where she was a partner for 5 years. Her industry career spans over 20 years, during which she held key positions in both start-up and large pharma companies. Her experience includes management and executive positions at Behringwerke, Chiron, MediGene, Borean Pharma, Telormedix and Trethera Corporation. She is chairman of Amal Therapeutics.
Dr. Holldack has a medical degree from Georg-August-University in Göttingen, Germany and is a board certified pediatrician. In addition, she has held positions as an assistant professor at the University of Essen, research fellow for the Deutsche Krebshilfe and a research associate at Harvard Medical School.
Johanna Holldack holds no shares in Photocure.
She is Chair of the Compensation Committee.
Neal Shore, Director
Dr. Shore is Medical Director for the Carolina Urologic Research Center and is a Fellow of the American College of Surgeons. He has conducted more than 350 clinical trials focusing mainly on genitourinary oncology. Dr. Shore performs peer reviews for Lancet Oncology, New England Journal of Medicine, European Urology, the Journal of Urology, Urology, BJUI, PCPD, and other high-impact scientific journals. He serves on the executive boards of the Society of Urologic Oncology, the Bladder Cancer Advocacy Network (BCAN), and as the National Urology Research Director for GenesisCare. From 2016 to 2018 Dr. Shore was the President of the Large Urology Group Practice Association. In addition, he has served on a large number of Committees, Editorial and Review boards, such as the AUA Male Health and Data Committees, the SITC Task Force for Prostate Cancer, the Editorial Boards of Review in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE, Urology Practice, and the World Journal of Urology.
Neal Shore holds no shares or share options in Photocure.
Anders Tuv, Director
Anders Tuv is currently and has since 2011 been Investment Director at life science investment company Radforsk with a focus on immunotherapies and precision medicines. He is an experienced investment and business development professional with broad experience from the healthcare and biotech industry covering founding and building biotech companies, strategy and business development, R&D collaborations, licensing deals, due diligences, private placements, M&As and IPOs. Anders also has been part of the operational development of several biotechs. He holds an MBE degree. Anders holds several chairman and non-executive director positions in Norwegian biotech companies.
Anders Tuv holds no shares in Photocure.
He is Chair of the Audit Committee.
Anne Worsøe, Director
Anne Worsøe is Head of Investor Relations and Communication at Ultimovacs ASA. Previously, she was partner at Bakken & Bæck and Chair of Bakken & Bæck Invest, a digital studio specialized in product design, development and artificial intelligence. As Director of Innovation Norway in San Francisco, Anne initiated and co-founded Nordic Innovation House in Silicon Valley and launched an accelerator program for validating product-market fit in the USA. Prior to moving abroad, she held the position as Head of New Business at Statkraft, and she was the first CEO of the Norwegian Venture Capital & Private Equity Association.
She is currently Chair of the Board at First Seed foundation, and Venture Partner at Antler, a global early-stage venture capital firm.
Anne Worsøe holds no shares in Photocure.
She is Member of the Audit Committee and ESG representative at Photocure.
Daniel Schneider, President and Chief Executive Officer
Dan Schneider joined Photocure November 2018. He brings more than 25 years of experience in developing and expanding rapidly growing healthcare companies in the U.S., most recently as the General Manager for Ablynx N.V. in North America. He has also held executive management positions in other pharmaceutical and biotech companies, including BTG International, Somaxon Pharmaceuticals and Sepracor.
Mr. Schneider is a U.S. citizen and holds an MBA from Washington University and a Bachelor of Science degree in Business Administration from St. Louis University with a double major in Finance and Marketing.
Dan Schneider holds 195,000 share options and 99,484 shares in the Company.
Erik Dahl, Chief Financial Officer
Erik Dahl, joined Photocure in August 2012 as CFO. He has more than 30 years of experience from senior level financial management roles, with responsibilities within corporate finance, legal and financial restructurings, M&A and capital market transactions. He has held various CFO roles in both public and private companies. Mr. Dahl has a Bachelor degree in finance and accounting from the Norwegian School of Economics.
Erik Dahl holds 102,500 share options and 32,750 shares in the Company.
Geoffrey Coy, Vice President & General Manager North America
Geoff Coy joined Photocure in October 2019. He has nearly 25 years of experience in the life sciences industry including sales, marketing, sales operations and market access in the biopharmaceuticals and medical device areas. Prior to joining Photocure Geoff was the Commercial Vice President of Sales and Marketing for BTG International (Boston Scientific) where he lead strategic and operational business development. Prior to BTG Geoff has been in leadership roles for Sepracor Pharmaceuticals and GlaxoSmithKline. Geoff has a proven track record and ability to build and develop high-performing commercial teams that deliver results.
Geoffrey Coy holds 147,500 share options and 15,207 shares in the Company.
Grete Hogstad, Vice President Global Strategic Marketing & Business Development
Grete Hogstad, joined Photocure in February 2005 as VP Marketing & Sales, with main responsibility for building the commercial operations in the Nordic. She has a degree in pharmacy from the University of Oslo, as well as a business degree from the Norwegian School of Management. She has held various leading positions in R&D, commercial operations, marketing and brand management and business development in Alpharma and Novo Nordisk Pharma, and is a founding member of the Generics Association in Norway.
Grete Hogstad holds 77,500 share options and 30,719 shares in the Company.
Patricia Kelly, Vice President Global Human Resources
Patti Kelly joined Photocure in September 2020 after having worked with the company on due diligence, key personnel recruitment and acquisition of global rights for Hexvix® as an external HR advisor for several months. She brings over 25 years of HR leadership experience to the Company. Ms. Kelly was the Chief HR Officer for Capsugel, a global Pharma technology company where she established the global HR function for the private equity-owned company after they separated from Pfizer. She held this role until 2017 when she started her HR consulting business. Prior to Pfizer, she worked for Schering-Plough (Merck) where she held positions of increasing responsibility over 16 years with her last role as VP HR Animal Health and Consumer Health.
Ms. Kelly received a bachelor's degree in Business Administration from Montclair State University and an M.B.A. in Management from Fairleigh Dickenson University.
Patti Kelly holds 80,000 share options in the Company.
Anders Neijber, Vice President Global Medical Affairs and Clinical Development
Anders Neijber joined Photocure in August 2021, bringing over 25 years of substantial experience in the uro-oncology area and successful leadership in the pharmaceutical industry. He has had global and regional assignments, both in the U.S. and Europe, within Clinical R&D and Medical Affairs, having worked for Pfizer, AstraZeneca, Johnson & Johnson, Allergan and Ferring, where he held a similar global Medical Affairs leadership role as V.P., Global Therapeutic Area Head Uro-Oncology. Most recently he worked in Medical Affairs for Novartis in the Nordics.
Anders completed his MD and PhD from Karolinska University, is a board certified urologist, and also holds an MBA. He held an assistant Professor position at the Department of Clinical Pharmacology, Robert Wood Johnson Medical School, New Jersey.
Anders Neijber holds 28,000 share options in Photocure.
Susanne Strauss, Vice President & General Manager Europe
Susanne Strauss joined Photocure in July 2020 following Photocure's regaining worldwide rights to Hexvix® and the establishment of its own commercial operations in Europe. She brings over 20 years of international leadership experience in medical devices, life sciences and pharma, living and working across Europe and Asia with occasional remits in the U.S.
Most recently Ms. Strauss held the position of General Manager of Asia Pacific for legacy BTG at Boston Scientific after leading BTG's Interventional Pulmonology Business as VP Commercial and expanding BTG's Interventional Oncology Business into Europe. Before that she worked in leadership positions for Convatec, Janssen-Cilag and Baxter. She holds a PhD in Technical Chemistry and an MBA from SDA Bocconi.
Susanne Strauss holds 135,000 share options and 1392 shares in the Company.